Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients
Patients in the convalescent phase of COVID-19 who received sulodexide for eight weeks showed a reduction in TM, vWF, D-dimer, CRP, and IL-6 serum levels compared to placebo. These findings suggest a potential protective effect of sulodexide against thromboinflammation and endothelial damage.
Authors
- Jawed Fareed (ORCID: https://orcid.org/0000-0003-3465-2499)
- Alejandro J. Gonzalez-Ochoa (ORCID: https://orcid.org/0000-0001-5068-623X)
- Győző Szolnoky (ORCID: https://orcid.org/0000-0002-4457-0799)
- Ana G Hernandez-Ibarra
Institutions
- Loyola University Medical Center (US)
- University of Szeged (HU)
Publication Details
- Journal
- Clinical and Applied Thrombosis/Hemostasis
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/10760296241297647
- Citations
- 3
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.19